Perspectives on the development of neutralizing antibodies against SARS-CoV-2

@article{Ho2020PerspectivesOT,
  title={Perspectives on the development of neutralizing antibodies against SARS-CoV-2},
  author={Mitchell Ho},
  journal={Antibody Therapeutics},
  year={2020},
  volume={3},
  pages={109 - 114}
}
Abstract SARS-CoV-2 gains entry to human cells through its spike (S) protein binding to angiotensin-converting enzyme 2 (ACE2). Therefore, the receptor binding domain (RBD) of the S protein is the primary target for neutralizing antibodies. Selection of broad-neutralizing antibodies against SARS-CoV-2 and SARS-CoV is attractive and might be useful for treating not only COVID-19 but also future SARS-related CoV infections. Broad-neutralizing antibodies, such as 47D11, S309, and VHH-72, have been… Expand
Emerging antibody-based therapeutics against SARS-CoV-2 during the global pandemic
Antibodies and Vaccines Target RBD of SARS-CoV-2
Human neutralizing antibodies to SARS-CoV-2: views and perspectives from Professor Linqi Zhang at Tsinghua University
  • Yubin Li
  • Biology
  • Antibody therapeutics
  • 2020
Development and application of therapeutic antibodies against COVID-19
Fruitful Neutralizing Antibody Pipeline Brings Hope To Defeat SARS-Cov-2
...
1
2
3
...

References

SHOWING 1-10 OF 40 REFERENCES
A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
  • X. Chi, R. Yan, +21 authors Wei Chen
  • Medicine, Chemistry
  • Science
  • 2020
Structural and functional analysis of a potent sarbecovirus neutralizing antibody
Human neutralizing antibodies elicited by SARS-CoV-2 infection
Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2
Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig
A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV
...
1
2
3
4
...